---
title: "InnoCare Doses First Subject in Phase 1 Trial of Autoimmune Drug ICP-B161 in China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303660771.md"
description: "InnoCare Pharma has dosed the first subject in a Phase 1 trial of ICP-B161 in China. This bispecific antibody targets TL1A and IL-23p19 for autoimmune diseases like inflammatory bowel disease. Preclinical data showed symptom reduction and good tolerability, with an extended half-life supporting less frequent subcutaneous dosing. No such bispecific antibody is currently approved globally."
datetime: "2026-10-30T02:02:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303660771.md)
  - [en](https://longbridge.com/en/news/303660771.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303660771.md)
generator: "portal-rs"
---

# InnoCare Doses First Subject in Phase 1 Trial of Autoimmune Drug ICP-B161 in China

-   InnoCare Pharma dosed the first subject in a Phase 1 trial of ICP-B161 in China on Oct. 30, 2026. \* The bispecific antibody targets TL1A and IL-23p19 for potential treatment of autoimmune diseases, including inflammatory bowel disease. \* Preclinical studies showed significant reductions in colitis-related symptoms with good tolerability. \* Its extended half-life supports less frequent dosing and subcutaneous administration. \* No bispecific antibody targeting both TL1A and IL-23p19 has been approved worldwide. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610292201PRIMZONEFULLFEED9856744) on October 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)

## Related News & Research

- [InnoCare Doses First Patient in Phase I Trial of Cancer Drug ICP-B381 in China](https://longbridge.com/en/news/305175446.md)
- [2026 ASH Oral Presentation | InnoCare Announces Phase III Results of Orelabrutinib in ITP Study Meet Primary Endpoint](https://longbridge.com/en/news/304435812.md)
- [China Accepts InnoCare’s Orelabrutinib Application for ITP Treatment](https://longbridge.com/en/news/304433408.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [InnoCare Pharma Sets Board Meeting to Approve Q3 2026 Results](https://longbridge.com/en/news/301568017.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**